FDA
-
-
-
-
-
-
-
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
-
-
-
-
-
-
-
Clarus Therapeutics (CRXT) Announces Phase 4 Clinical Trial of JATENZO for the Treatment of Hypogonadal Men with Chronic Kidney Disease
-
-
-
-
-
-
-
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
-
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

